Two Big Pharma companies, GSK and Takeda, made moves this week to bolster their environmental sustainability efforts. GSK is focusing on its supply chain and Takeda on its electrical sources in the U.S. In GSK’s case, the development is part of a larger trend of companies focusing on emissions from outside of their direct operations. Fierce's Fraiser Kansteiner and Eric Sagonowsky will discuss what we can expect on environmental sustainability at Big Pharmas.

To learn more about topics in this episode: 

• GSK puts suppliers on the hook as it amps up sustainability crusade 
• A $3M gene therapy: Bluebird bio breaks its own pricing record with FDA approval of Skysona
• Merck finally gets FDA nod to relaunch HIV trials, but drops preventive therapy plans
• FDA plans advisory committee meeting to discuss racial bias built into pulse oximeters
• Smartphone cameras could replace pulse oximeters to measure blood oxygen at home: study
• Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

The Top Line is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

See omnystudio.com/listener for privacy information.